Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-247-0 | CAS number: 563-41-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1986
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Semicarbazide hydrochloride
- EC Number:
- 209-247-0
- EC Name:
- Semicarbazide hydrochloride
- Cas Number:
- 563-41-7
- Molecular formula:
- CH5N3O.ClH
- IUPAC Name:
- semicarbazide hydrochloride
Constituent 1
- Specific details on test material used for the study:
- SC hydrochloride (Supplier Merck) was dissolved in 1 mL of saline solution at a concentration of 0,9% NaCl and a final pH of 7,2. The animals were weighed at the moment of injection in order to calculate the mg of SC to be added to the mL of saline solution necessary for the dosis indicated by kg of weight.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- Female rats : Virgin
Weight at the beginning of the study : 200-250g
Food : standard rat died ad libitum
Water :ad libitum
Room temperature : 25+/-2°C
Light cycles : 12 hours light/12 hours dark, automatically regulated
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- other: Saline solution of NaCl
- Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- Virgin female Wistar rats were bred in estrus during the early afternoon and remainded caged with fertile male Wistar rats overnight (4 females to 2 males)
Pregnancy diagnosis was determined by vaginal smears. - Duration of treatment / exposure:
- One group is injected with 17 mg/kg/day C throughout gestation
Another group on day 5, 7, 10, 13 or 15 of gestation with 50, 75, 100 or 150 mg/kg SC respectively - Frequency of treatment:
- One group is injected with 17 mg/kg/day C throughout gestation
Another group on day 5, 7, 10, 13 or 15 of gestation with 50, 75, 100 or 150 mg/kg SC respectively
- No. of animals per sex per dose:
- All the experimental (single and coninuous dose) and control animals were divided into 2 groups : A and B.
Group A was made of 190 experimental animals.
Group B was made of 105 experimental pregant animal and 30 controls. - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Control animals received the same volume of saline solution intraperitoneally on a similar schedule i e on the day of gestation corresponding to that of the treated (experimental) animals.
10 pregnants females were used as controls for each of the days (5, 7, 10, 13 or 15) of gestation in which SC was administered.
Another 10 females controls received 1 mL saline solution daily during the whole gestation.
The animals of the group A were sacrified on day 21 of gestation. A midline abdominal incision was performed and both uterine horns were exposed.
Live and dead fetuses were removed and counted together with the number of resoprtions and implantations.
All fetuses were carefully examined for signs of externals malformations and their sex and weight noted down.
The live fetuses were then subdivided at random into 2 subgroups, a and b, in order to carry out a specific study in each of the subgroups.
In subgroup a, organic anomalies were studied. The fetuses were placed in Bouin's fluid, and their internal organs were then examined by sectioning with a razor blade following Wilson's technique..
The fetuses in subgroup b, were used to study the skeleton anomalies. They were fixed in 70% ethanol and then cleared with 1% OHK and stained with alizarin red S.
Group B: all animals from this group were allowed to deliver, and the mortality rate of their offspringwas studied during the first month of life.
Examinations
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: No
- Number of implantations: Yes
- Number resorptions: Yes - Fetal examinations:
- - External examinations: Yes
- Soft tissue examinations: No data
- Skeletal examinations: Yes:
- Head examinations: No data
- Internal organs : Yes - Statistics:
- The mean +/-SEM values for treated and non-treated (control) fetuses were statistically compared with a 2-tail Student's t test. p<0.05 being the minimum significant value.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Some maternal deaths ensued after treatment with the 50, 100 and especially 150 mg/kg SC regimen.
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Maternal developmental toxicity
- Number of abortions:
- not specified
- Pre- and post-implantation loss:
- not specified
- Total litter losses by resorption:
- effects observed, treatment-related
- Description (incidence and severity):
- There were several degrees of resoprtion rates as well deaths almost every day with all the doses studied.
The resroption rate were directly correlated with the dose; while the number of live fetuses was inversely related to it.
Treatment with SC was most embryotoxic onday 7 abd 10 of gestation, with statistically significant differences in the number of live fetuses with respect to controls with all the doses used.
The administration of SC on day 5 produced a significant decrease in the number od live fetuses only with the 100 mg/kg dose while on day 13 and 15 this occured with the 100 and 150 mg/kg doses.
The percentage of resorptions, expressed as small, medium or large in size and appaearing on the different days of treatment, were for days 5, 7, 10, 13 and 15 : 48, 27, 25, 3 and 0%, for the samll resorptions; 52, 68, 39, 38 and 32% respectively for the medium resorptions and 0, 4, 36, 52 and 68% respectively for the large resorptions. - Early or late resorptions:
- not specified
- Dead fetuses:
- not specified
- Changes in pregnancy duration:
- not specified
- Changes in number of pregnant:
- not specified
- Other effects:
- not specified
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- conc. level:
- Effect level:
- >= 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- mortality
- Remarks on result:
- other: NA
Maternal abnormalities
- Abnormalities:
- not examined
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Fetal weight is significantly decreased with all the doses used when these were admninistered on days 5, 7 or 10 of gestation.
With the 75, 100 and 150 mg/kg doses, fetal weight was significantly decreased on all the days of gestation in which SC was administered. - Reduction in number of live offspring:
- effects observed, treatment-related
- Changes in postnatal survival:
- effects observed, treatment-related
- Description (incidence and severity):
- SC produced a high mortality rate with high statistical differences as compared to controls on all the days and with all the doses studied.
Mortality was highest when SC was administered on day 10 of gestation (63+/-3% beign the highest value found and corresponding to the 100 mg/kg dose). - External malformations:
- not specified
- Skeletal malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- The most frequent skeletal lesions found were an incomplete ossification of the skull and sternum, especially when SC was administered during the implantation period.
A small percentage of lesions was also found in the ribs. An incomplete ossification of the limbs also occured.
The malformations found in the fetuses whose mothers were injected with 17 mg/kg/day SC during the entire course of pregnancy were similar to the ones mentioned for the single-dose treatment; although the hemorrhages in the liver and hydronephroses were less frequent. - Visceral malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- The fetuses showed some abnormalities in the brain, especially when the rats were treated during the differentiation period.
These abnormalities were mainly internal hydrocephaly, and in somes cases, exencephaly and meningocele.
Severe hemorrhages in liver and intentines were also observed in the fetuses treated during this period.
A high percentage of hydronephroses appeared in the fetuses, regardless of the period in which their mothers were treated, although the percentage was higher during the developmental period.
A small percentage of anophtalmia on one side, cleft palate or an absence of testes was also observed in the fetuses which came to term. - Other effects:
- not specified
Effect levels (fetuses)
- Key result
- Dose descriptor:
- LOEL
- Effect level:
- < 17 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- skeletal malformations
- Remarks on result:
- other: NA
Fetal abnormalities
- Key result
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- external: limb
- skeletal: skull
- skeletal: sternum
- skeletal: rib
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 17 mg/kg bw/day (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects in the absence of maternal toxicity effects
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- SC produced a significantly smaller number of live fetuses with respect to controls.
This toxic effect after injection at days 7 and 10 of gestation was highest for all single doses.
The mean of fetal weight decreased with respect to controls with almost all of the SC treatment studied.
The number of implantations and live fetuses was significantly decreased in the rats receiving the continuous treatment.
Most abnormalities in the 21-day-old fetuses wre found in the brain, kidney, intestines and liver; skeletal anomalies were seen in the skull, sternuum and ribs.
SC also produced high postnatal mortality rates during the first month of life with the single doses as well as the continuous treatment.
Thus, SC produced signs of toxicity and/or teratogenic effects in rats with all doses administered. - Executive summary:
In a developmental and teratogenicity toxicity study (published), 5 groups of pregnant Wistar rats were injected intraperitoneally with a single dose of SemiCarbazide (SC) on days 5, 7, 10, 13 or 15 of gestation. The lots in each group received either 50, 75, 100 or 150 mg/kg SC. A sixth group received 17 mg/kg of the drug during ther entire course of pregnancy.
Results indicate that SC has an embryotoxic effect on Wistar rats when it was administered intraperitoneally in single doses of 50, 75, 100 pr 150 mg/kg on the different gestation days studied or in daily injections of 17 mg/kg throughout the entire course of pregnancy.
One of the most notable effect of this substance wasfetal death and resorption, resulting in a significant decrease in the number of live fetuses with respect to controls.
The embryotoxicity of SC as seen from the number of resorbed or dead conceptuses may provide an interesting correlation as to the extent of its teratogenicity.
The dosage levels producing these effects also caused some maternal toxicity. However, some pregnant females who did not show anu overt signs of toxicity had litters with malformed embryos. Thus, the embryotoxic consequences of SC treatment were due to a direct action on the embryo (and not to an indirect effect through the mother).
Intrauterine growth (weight of the 21 -day old fetuses) was decreased with the single dose injections but not with the continuous treatment. The decrease in the number of live fetuses and implantations per litter, however, wss more notable with the coninuous treatment.
Thus from the results foundon the relationship between resorption sizes and days injected, it is possible to infer taht SC acts on intrauterine life, stopping its growth one the drug is administered.
A slight increase in the number of organic lesions when SC was injected during the differentiation period (which corresponds to the teratogenic susceptibility othe rat during these days 9 and 10 of gestation) has been observed. Abnormatlities in the brain, the kidney, intestines and liver ; skeletal aomalies were seen in the skull, sternuum and ribs. SC produced also high postnatal mortality rates during the first month of life with the single doses as well as with the continuous treatment.
Tus, SC produced signs of toxicity and/or teratogenic effects in rats with all doses administered.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.